Literature DB >> 2485900

Adenosine decreases the fibrillation threshold in atrial myocardium.

J Szegi1, A J Szentmiklósi, A Cseppentö.   

Abstract

The action of adenosine on the fibrillation threshold, effective refractory period, electric diastolic threshold and mechanical activity of the atrial and ventricular myocardium was studied in vivo and in vitro. In anaesthetized, open-chest cats, the atrial fibrillation threshold significantly decreased under adenosine-infusion (1 mumols/kg/min). In electrically stimulated atrial myocardium of cats, adenosine (10 mumols/l-1 mmol/l) was capable of evoking a concentration-dependent decrease in electric diastolic threshold and shortening the functional refractory period. Adenosine decreased also the contractile force. The shortening on the functional refractory period was more prominent in electrically driven guinea-pig left atrial myocardium. This action could be antagonized by aminophylline, a competitive antagonist on P1 purinoceptors. In ventricular myocardium, adenosine did not influence the fibrillation threshold, the electric diastolic threshold, the functional refractory period or contractile force. On the basis of these observations it can be assumed that the above changes in the extracellular electrophysiological parameters may play a role in the pathomechanism of atrial fibrillation occasionally manifested during treatment with adenosine in patients as well as in dogs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2485900

Source DB:  PubMed          Journal:  Pol J Pharmacol Pharm        ISSN: 0301-0244


  2 in total

Review 1.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

2.  Role of endogenous adenosine in atrial fibrillation after coronary artery bypass graft.

Authors:  Turhan Yavuz; Barry Bertolet; Yavuz Bebooul; Bulent Tunerir; Recep Aslan; Ahmet Ocal; Erdooan Ybribim; Ali Kutsal
Journal:  Clin Cardiol       Date:  2004-06       Impact factor: 2.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.